Answers are grounded in this paper and cite their sources.
To study the possible reversibility of platinum−protein binding, the platinum−methionine and platinum−cysteine model adducts cis-[Pt(NH3)2(GSMe)2]2+, [Pt(dien)(GSMe)]2+, [Pt(dien)(GS)]+, and {[Pt(dien)]2(GS)}3+ (GSH = glutathione, GSMe = S-methylglutathione) have been reacted with 5‘-AMP and 5‘-GMP and d(GpG) under a variety of reaction conditions. Only 5‘-GMP and d(GpG) were found to substitute GSMe (a Pt−thioether bond) from [Pt(dien)(GSMe)]2+, forming [Pt(dien)(GMP−N7)]2+ and {Pt(dien)[d(GpG)-N7)]}2+, respectively. Reacting the GSMe diadduct of cisplatin [cis-Pt(NH3)2(GSMe)2]2+ with GMP revealed that the N7 of 5‘-GMP can also substitute GSMe on cisplatin, forming cis-[Pt(NH3)2(GSMe)(GMP−N7)]2+ and the GMP diadduct cis-[Pt(NH3)2(GMP−N7)2]2+. The platinum−cysteine model adducts [Pt(dien)(GS)]+ and {[Pt(dien)]2(GS)}3+, however, did not react with 5‘-AMP or 5‘-GMP at 37 °C. Kinetic experiments have revealed that the intermolecular rearrangement reaction of Pt(dien)2+ from thioether sulfur to 5‘-GMP is second order and that the reaction is slow at ambient temperature (t1/2 = 179 h). At 35 °C the reaction proceeds with a reaction rate (t1/2 = 31 h), which appears as a relevant rate for in vivo processes. The obtained results are discussed in relation to the antitumor activity and toxicity of platinum complexes. The data suggest that the existence of a drug reservoir is limited to platinum−thioether-type adducts and that the observed rearrangement only occurs with the N7 of guanine and not with adenine. Consequently, new platinum amine chelate complexes in which a thioether function is present as a leaving group might be successful as platinum antitumor compounds exhibiting reduced toxic side effects.
No takes yet. Share an insight, caveat, or question.
Boom et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: